Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.64 |
| ▸ | TAS1R1 | Q7RTX1 | 14/20 | 0.64 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744346 | 0.88 | TAS1R3 (0.50) | TAS1R3TAS1R1CTSKCTSLBCAT1 | |
| SCHEMBL5744609 | 0.87 | CTSK (0.70) | TAS1R3TAS1R1CTSKCTSLCTSB | |
| SCHEMBL5743949 | 0.86 | CTSK (0.57) | TAS1R3TAS1R1CTSKCTSLCTSB | |
| SCHEMBL5743549 | 0.80 | CTSK (0.60) | TAS1R3TAS1R1CTSKCTSLCTSB | |
| SCHEMBL10226450 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1 | |
| SCHEMBL4201557 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1 | |
| SCHEMBL12670005 | 0.78 | TAS1R3 (0.61) | TAS1R3TAS1R1CTSKCTSL | |
| SCHEMBL5745635 | 0.76 | CTSK (0.49) | TAS1R3TAS1R1CTSKCTSLCTSB | |
| SCHEMBL8283411 | 0.76 | TAS1R3 (0.58) | TAS1R3TAS1R1CTSK | |
| SCHEMBL5743287 | 0.76 | CTSK (0.69) | CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | TAS1R3 977/4885TAS1R1 1274/4885CTSK 4/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | TAS1R3 1604/4885TAS1R1 2087/4885CTSK 5/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | TAS1R3 442/4885TAS1R1 351/4885CTSK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.